Rhabdomyosarcomas utilize developmental, myogenic growth factors for disease advantage: A report from the children's oncology group

Mary C. Blandford, Frederic G. Barr, James C. Lynch, R Randall, Stephen J. Qualman, Charles Keller

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Background. Unresectable or metastatic disease represents the greatest obstacle to cure for children with rhabdomyosarcoma. In this study we sought to identify gene expression signatures of advanced stage and progressive disease. Procedure. Using oligonucleotide gene expression analysis for a focused set of 60 genes, we analyzed the myogenic expression profiles of 89 rhabdomyosarcomas from the Intergroup Rhab-domyosarcoma Study-IV. Results. While the expression profile of rhabdomyosarcomas closely paralleled gene expression profiles of normal embryonic myogenic progenitors, growth factors were most closely associated with disease progression. Specifically, we identified platelet-derived growth factor (PDGF) receptors and insulin-like growth factor as strongly correlated with decreased failure-free survival. Real-time reverse transcriptase polymerase chain reaction (RT-PCR) of an independent data set suggested that autocrine growth signaling, if present, is not regulated in a simple manner at the transcriptional level. Conclusions. Increased transcriptional levels of PDGF receptors and insulin-like growth factor are associated with decreased survival in rhabdomyosarcomas. Dual blockade of these growth-factor-signaling pathways may be a valuable strategy in preclinical therapeutic studies.

Original languageEnglish (US)
Pages (from-to)329-338
Number of pages10
JournalPediatric Blood and Cancer
Volume46
Issue number3
DOIs
StatePublished - Mar 1 2006
Externally publishedYes

Fingerprint

Rhabdomyosarcoma
Intercellular Signaling Peptides and Proteins
Platelet-Derived Growth Factor Receptors
Somatomedins
Transcriptome
Autocrine Communication
Reverse Transcriptase Polymerase Chain Reaction
Oligonucleotides
Disease Progression
Real-Time Polymerase Chain Reaction
Gene Expression
Growth
Genes
Therapeutics

Keywords

  • Insulin-like growth factor
  • Metastasis
  • Myogenesis
  • Platelet-derived growth factor
  • Progression
  • Rhabdomyosarcoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Rhabdomyosarcomas utilize developmental, myogenic growth factors for disease advantage : A report from the children's oncology group. / Blandford, Mary C.; Barr, Frederic G.; Lynch, James C.; Randall, R; Qualman, Stephen J.; Keller, Charles.

In: Pediatric Blood and Cancer, Vol. 46, No. 3, 01.03.2006, p. 329-338.

Research output: Contribution to journalArticle

Blandford, Mary C. ; Barr, Frederic G. ; Lynch, James C. ; Randall, R ; Qualman, Stephen J. ; Keller, Charles. / Rhabdomyosarcomas utilize developmental, myogenic growth factors for disease advantage : A report from the children's oncology group. In: Pediatric Blood and Cancer. 2006 ; Vol. 46, No. 3. pp. 329-338.
@article{c1666aac532741e0bbd956fad442a682,
title = "Rhabdomyosarcomas utilize developmental, myogenic growth factors for disease advantage: A report from the children's oncology group",
abstract = "Background. Unresectable or metastatic disease represents the greatest obstacle to cure for children with rhabdomyosarcoma. In this study we sought to identify gene expression signatures of advanced stage and progressive disease. Procedure. Using oligonucleotide gene expression analysis for a focused set of 60 genes, we analyzed the myogenic expression profiles of 89 rhabdomyosarcomas from the Intergroup Rhab-domyosarcoma Study-IV. Results. While the expression profile of rhabdomyosarcomas closely paralleled gene expression profiles of normal embryonic myogenic progenitors, growth factors were most closely associated with disease progression. Specifically, we identified platelet-derived growth factor (PDGF) receptors and insulin-like growth factor as strongly correlated with decreased failure-free survival. Real-time reverse transcriptase polymerase chain reaction (RT-PCR) of an independent data set suggested that autocrine growth signaling, if present, is not regulated in a simple manner at the transcriptional level. Conclusions. Increased transcriptional levels of PDGF receptors and insulin-like growth factor are associated with decreased survival in rhabdomyosarcomas. Dual blockade of these growth-factor-signaling pathways may be a valuable strategy in preclinical therapeutic studies.",
keywords = "Insulin-like growth factor, Metastasis, Myogenesis, Platelet-derived growth factor, Progression, Rhabdomyosarcoma",
author = "Blandford, {Mary C.} and Barr, {Frederic G.} and Lynch, {James C.} and R Randall and Qualman, {Stephen J.} and Charles Keller",
year = "2006",
month = "3",
day = "1",
doi = "10.1002/pbc.20466",
language = "English (US)",
volume = "46",
pages = "329--338",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Rhabdomyosarcomas utilize developmental, myogenic growth factors for disease advantage

T2 - A report from the children's oncology group

AU - Blandford, Mary C.

AU - Barr, Frederic G.

AU - Lynch, James C.

AU - Randall, R

AU - Qualman, Stephen J.

AU - Keller, Charles

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Background. Unresectable or metastatic disease represents the greatest obstacle to cure for children with rhabdomyosarcoma. In this study we sought to identify gene expression signatures of advanced stage and progressive disease. Procedure. Using oligonucleotide gene expression analysis for a focused set of 60 genes, we analyzed the myogenic expression profiles of 89 rhabdomyosarcomas from the Intergroup Rhab-domyosarcoma Study-IV. Results. While the expression profile of rhabdomyosarcomas closely paralleled gene expression profiles of normal embryonic myogenic progenitors, growth factors were most closely associated with disease progression. Specifically, we identified platelet-derived growth factor (PDGF) receptors and insulin-like growth factor as strongly correlated with decreased failure-free survival. Real-time reverse transcriptase polymerase chain reaction (RT-PCR) of an independent data set suggested that autocrine growth signaling, if present, is not regulated in a simple manner at the transcriptional level. Conclusions. Increased transcriptional levels of PDGF receptors and insulin-like growth factor are associated with decreased survival in rhabdomyosarcomas. Dual blockade of these growth-factor-signaling pathways may be a valuable strategy in preclinical therapeutic studies.

AB - Background. Unresectable or metastatic disease represents the greatest obstacle to cure for children with rhabdomyosarcoma. In this study we sought to identify gene expression signatures of advanced stage and progressive disease. Procedure. Using oligonucleotide gene expression analysis for a focused set of 60 genes, we analyzed the myogenic expression profiles of 89 rhabdomyosarcomas from the Intergroup Rhab-domyosarcoma Study-IV. Results. While the expression profile of rhabdomyosarcomas closely paralleled gene expression profiles of normal embryonic myogenic progenitors, growth factors were most closely associated with disease progression. Specifically, we identified platelet-derived growth factor (PDGF) receptors and insulin-like growth factor as strongly correlated with decreased failure-free survival. Real-time reverse transcriptase polymerase chain reaction (RT-PCR) of an independent data set suggested that autocrine growth signaling, if present, is not regulated in a simple manner at the transcriptional level. Conclusions. Increased transcriptional levels of PDGF receptors and insulin-like growth factor are associated with decreased survival in rhabdomyosarcomas. Dual blockade of these growth-factor-signaling pathways may be a valuable strategy in preclinical therapeutic studies.

KW - Insulin-like growth factor

KW - Metastasis

KW - Myogenesis

KW - Platelet-derived growth factor

KW - Progression

KW - Rhabdomyosarcoma

UR - http://www.scopus.com/inward/record.url?scp=32044469857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32044469857&partnerID=8YFLogxK

U2 - 10.1002/pbc.20466

DO - 10.1002/pbc.20466

M3 - Article

C2 - 16261596

AN - SCOPUS:32044469857

VL - 46

SP - 329

EP - 338

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 3

ER -